NEW YORK, April 12, 2017 /PRNewswire/ --
According to a research report by Market Research Future, the Cannabis market in North
America was valued at over USD 3.5 billion for the full year of 2015. Of that, the United States being the largest market in the region, was valued over USD 3
billion on its own. Marketing activities for cannabis products have been challenged by consumer perception and stern
federal policies. So as these issues are being tackled over time, the cannabis derivative is expected to witness a wider scale
adoption across the region, and is projected to grow over $16 billion by 2021, growing at a CAGR
over 29%. ChineseInvestors.com, Inc. (OTC: CIIX), Axim Biotechnologies, Inc. (OTC: AXIM), Vitality Biopharma, Inc. (OTC:
VBIO), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics Inc. (NASDAQ: CARA)
A major portion of the cannabis industry is the Cannabidiol (CBD) market. CBD is widely used for medical products, and is
not psychoactive, therefore not useful for reactional purposes. The Hemp Business Journal estimated that the CBD market will
grow to a $2.1 billion market in consumer sales by 2020, with $450
million of those sales coming from hemp-based sources. That's a 700% increase from 2016.
ChineseInvestors.com, Inc. (OTCQB: CIIX) on March 30th, announced its investment in
Breakwater MB, LLC, a cannabis-focused investment and consulting company. Building on the success that CIIX enjoyed through its
investment in early-stage firm Medicine Man Technologies, the Company is pleased to announce another strategic investment in the
cannabis industry.
Breakwater MB was formed by CIIX board member and former CFO, Paul Dickman, as a means to invest capital in and
provide consulting services to, private, cannabis-focused companies as they transition into the public market. The invested
capital will primarily be used to cover the costs of becoming a publicly traded company, a strategy CIIX expects will provide
significant investment appreciation and opportunity for liquidity. All opportunities will be evaluated by the investment
committee, comprised of CIIX CEO, Warren Wang, Medicine Man Technologies, CEO, Andy Williams, and Paul Dickman,
the CFO of Medicine Man and managing member of Breakwater MB."
"With the gradual opening up of the cannabis industry in the U.S., the potential development of cannabis companies will be
huge in the future. U.S. states will continue to issue cannabis licenses to applicants, while licensed cannabis stores will
continue to have long queues of consumers. As a result, I believe that CIIX will recognize generous returns from this investment
in a cannabis-focused investment and consulting company," says Wang.
Axim Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and production of cannabis-based
pharmaceutical, nutraceutical and cosmetic products. The company's flagship products include CanChew®, a CBD-based
controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of
pain and spasticity associated with multiple sclerosis. On March 07th, 2017, the company announced
enrollment of 40 patients and commencement of its Phase II clinical trial, for the treatment of irritable bowel syndrome (IBS)
with the company's CanChew Plus® CBD gum.
Vitality Biopharma, Inc. (OTCQB: VBIO) dedicates to the development of cannabinoid prodrug pharmaceuticals, and to
unlock the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. In March, the company
announced that it has positive results indicating a new use for the Company's proprietary prodrug cannabinoid delivery platform.
Vitality found that cannabidiol (CBD) universally inhibited cell growth at concentrations similar to established
chemotherapeutics. The company also found that its cannabidiol prodrug was not toxic to the human cells at the concentrations
tested, demonstrating the relative safety of its prodrug delivery system.
Zynerba Pharmaceuticals, Inc . (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company focused on
developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal
delivery. On March 13, 2017, the company announced that it has completed enrollment in the Phase 2
STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, evaluating ZYN002 cannabidiol (CBD)
gel in adult epilepsy patients with refractory focal seizures. The Company also announced that enrollment has completed in the
Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial
evaluating ZYN002 CBD gel for the treatment of osteoarthritis.
Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biotechnology company focused on developing and
commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid
receptors. The company is developing lead molecules that selectively modulate peripheral cannabinoid (CB) receptors without
targeting CNS cannabinoid receptors. Cara's most advanced CB compound, CR701, is in preclinical development. Administration of
CR701 to animals with neuropathy resulted in significant reversal of both hyperalgesia and allodynia, as measured by responses to
thermal and tactile stimuli, respectively.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts
on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site or other editorials for
advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news.
FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media
platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be
compensated three thousand dollars for financial news dissemination and pr services by
chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on
this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement
and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with
chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr
services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR
advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information
about any companies the information contained herein is not intended to be used as the basis for investment decisions and should
not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to
buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result
from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended
from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase,
hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor.
This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and
tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com